What Medications Can Cause a False Positive for Benzos?

Several commonly prescribed medications can trigger false-positive benzodiazepine results on standard urine drug screens, including the antidepressant sertraline (Zoloft), the anti-inflammatory drug oxaprozin (Daypro), and the HIV medication efavirenz (Sustiva). The problem lies not with the medications themselves but with the screening technology, which relies on antibody-based reactions that sometimes mistake a non-benzodiazepine molecule for the real thing. Understanding which drugs are known offenders and what to do when a result looks wrong can save you from serious consequences in clinical, employment, and legal settings.

How Screening Tests Get It Wrong

Standard urine drug screens use immunoassay technology. The test contains antibodies designed to bind to benzodiazepines or their metabolites. When a urine sample is added, these antibodies react if they detect molecules shaped similarly to benzodiazepines. The trouble is that antibodies are not perfectly selective. A molecule with a similar enough three-dimensional shape or chemical structure can bind to the antibody and produce a signal that the test reads as positive.

This is why the results from immunoassay screens are considered “presumptive” rather than definitive. The test is designed to be sensitive, catching as many true positives as possible, but that sensitivity comes at the cost of specificity. Some non-benzodiazepine compounds share just enough structural resemblance to fool the antibodies. Different manufacturers use different antibodies in their assay kits, which means the list of cross-reacting substances varies depending on which test platform a laboratory uses. A medication that triggers a false positive on one brand of immunoassay might not cause a problem on another.

Sertraline (Zoloft)

Sertraline, one of the most widely prescribed antidepressants in the world, has been linked to false-positive benzodiazepine results on urine screens. A retrospective chart analysis reviewed 522 records of patients who tested positive for benzodiazepines on a screening immunoassay. Of those, 160 turned out to be false positives after confirmatory testing with gas chromatography-mass spectrometry. Among the 98 false positives in patients who were not taking any prescribed benzodiazepine, 26 were associated with a concurrent sertraline prescription.¹ That is a meaningful proportion, and the authors concluded that sertraline may be an unreported cause of false positives in widely used screening assays.

What makes this finding particularly relevant is how common sertraline is. Millions of people take it for depression, anxiety, obsessive-compulsive disorder, and other conditions. If you are on sertraline and face a workplace drug screen or a test ordered by a pain management clinic, the possibility of a false-positive benzodiazepine result is worth knowing about in advance. You can alert the testing provider to your medication list, and if the initial screen comes back positive, request confirmatory testing before any conclusions are drawn.

Oxaprozin (Daypro)

Oxaprozin is a prescription nonsteroidal anti-inflammatory drug used for arthritis and other inflammatory conditions. It has one of the most well-documented cross-reactivity profiles for benzodiazepine immunoassays. A report in JAMA alerted physicians that oxaprozin could cause false-positive benzodiazepine results on urine drug panels.²

Follow-up research tested oxaprozin’s cross-reactivity across three major commercial immunoassay platforms. All 36 urine specimens collected from 12 subjects who had taken oxaprozin produced positive benzodiazepine results on two of the three assay systems, and 35 out of 36 were positive on the third.³ In other words, nearly everyone taking oxaprozin will test positive for benzodiazepines on a standard urine screen. The cross-reactivity was observed at concentrations far above the typical cutoff threshold, making the false positive essentially inevitable while the drug is in your system.

Oxaprozin is worth paying special attention to because it has a very long half-life compared to other NSAIDs. The drug and its metabolites can linger in your body for days after a single dose, meaning the window for a false-positive result is wider than you might expect. If you are prescribed oxaprozin and know a drug screen is coming, this is one of the easiest false-positive scenarios to anticipate and address proactively.

Efavirenz (Sustiva)

Efavirenz, an antiretroviral medication used in the treatment of HIV, produces perhaps the most striking false-positive profile of any medication studied. Researchers tested urine samples from 100 HIV-positive patients, 50 of whom were taking efavirenz and 50 who were not. Among those on efavirenz, 49 out of 50 tested positive for benzodiazepines on at least one drug screening test. Among those not on efavirenz, only 1 out of 50 tested positive.⁴ The culprit is a metabolite called 8-hydroxy-efavirenz, which the body produces when it breaks down efavirenz and which mimics benzodiazepine structure closely enough to trigger the immunoassay.

A 98% false-positive rate is extraordinary and makes efavirenz practically guaranteed to produce a misleading result. This is especially concerning given the social and legal complexities that can surround drug testing for people living with HIV. Some patients may be reluctant to disclose their HIV status or medication list, and a benzodiazepine false positive in a probation, custody, or employment context could have real consequences. Healthcare providers and testing laboratories that serve HIV-positive populations should be aware that efavirenz will almost always trigger this specific false alarm.

Other Medications That May Cross-React

The three medications above have the strongest published evidence behind them, but they are not the only substances that have been flagged. The broader literature on immunoassay cross-reactivity includes scattered reports involving other drug classes. Tolmetin, another NSAID in the same family as oxaprozin, has been reported to cause similar issues with benzodiazepine screens, though it is prescribed much less commonly today. Some antihistamines, particularly older, sedating ones, have appeared in case reports as well.

The challenge with building a comprehensive list is that cross-reactivity depends heavily on the specific assay platform in use. Manufacturers of immunoassay kits typically publish a list of substances they have tested for cross-reactivity, but these lists are not exhaustive. A drug might cause false positives on one company’s assay and not another’s. This means the answer to “what can cause a false positive” is partly “it depends on which test was used,” a frustrating reality for patients and providers alike. A review article in the American Journal of Health-System Pharmacy concluded that verification with a different screening test or additional confirmatory analysis should be performed to avoid adverse consequences for patients whenever a positive result is unexpected.⁵

What Confirmatory Testing Actually Does

When a urine immunoassay flags a sample as positive for benzodiazepines, the standard next step is confirmatory testing using a more precise analytical method, typically liquid chromatography-tandem mass spectrometry (LC-MS/MS) or gas chromatography-mass spectrometry (GC-MS). These instruments identify the exact molecules present in the sample rather than relying on antibody binding. They can distinguish sertraline metabolites from diazepam metabolites, for instance, or confirm that oxaprozin rather than alprazolam is responsible for the initial positive signal.

Confirmatory testing is highly accurate when it targets the right compounds. One study comparing immunoassay results to LC-MS/MS confirmatory panels found that the immunoassay had variable cross-reactivity, which explained both false-positive and false-negative results. When the LC-MS/MS panel was expanded to include a wider range of drugs, the number of results classified as “falsely positive” dropped substantially.⁶ In practical terms, this means confirmatory testing can clear your name if your positive result was caused by a cross-reacting medication, but only if it is ordered and if the lab runs a panel broad enough to detect the actual substance.

Not every testing situation automatically includes confirmatory testing. Workplace drug screens conducted under federal guidelines typically require confirmatory analysis before a result is reported as positive. But point-of-care tests used in emergency departments, pain clinics, and some probation settings may not trigger the same follow-up. If you receive a positive result and believe it to be wrong, you have the right to request confirmatory testing. Being able to name the specific medication you suspect is responsible makes it easier for the lab to identify the source of the cross-reactivity.

The Other Side of the Coin: False Negatives

While false positives understandably get more attention from patients worried about being wrongly flagged, false negatives are a significant and under-discussed problem with benzodiazepine immunoassays. A false negative occurs when a person is genuinely taking a benzodiazepine but the test fails to detect it. This can lead clinicians to mistakenly believe a patient is not complying with their prescribed treatment or is diverting their medication.

Lorazepam (Ativan) is one of the worst offenders for false negatives. The most widely used commercial benzodiazepine immunoassays have poor cross-reactivity with lorazepam’s primary urinary metabolite, lorazepam glucuronide. One manufacturer listed 62% cross-reactivity with lorazepam itself, but this figure is misleading because lorazepam is eliminated mostly as the glucuronide form in urine, and the cross-reactivity with that metabolite is negligible, around 0.5%. Studies of point-of-care assays have shown a false-negative rate of about 50% for lorazepam, meaning the test misses half the people who are actually taking it.⁷

Clonazepam (Klonopin) faces a similar problem. Point-of-care immunoassay cups frequently failed to produce positive results for patients confirmed by LC-MS/MS to be taking lorazepam or clonazepam. One study found that point-of-care assays yielded false-negative results for patients prescribed benzodiazepines nearly 20% of the time overall.⁸ If you are prescribed lorazepam or clonazepam and your urine screen comes back negative, it does not necessarily mean the test worked correctly. It may simply mean the assay is blind to those particular drugs.

The implication is that benzodiazepine immunoassays are unreliable in both directions. They can say yes when the answer is no, and they can say no when the answer is yes. The specific drugs they miss and the specific drugs they falsely detect vary by manufacturer and assay generation, creating a patchwork of accuracy that no single cheat sheet can fully resolve.

Point-of-Care Tests Versus Laboratory Assays

Not all immunoassays are created equal. The rapid test cups used in doctor’s offices, emergency rooms, and some clinics are point-of-care devices that trade accuracy for speed and convenience. Laboratory-based immunoassays, while still using the same antibody-based principle, tend to perform somewhat better because they run under more controlled conditions and use larger sample volumes.

The practical difference matters. Point-of-care cups are the tests most likely to produce both false positives and false negatives. They are also the tests least likely to be automatically followed up with confirmatory analysis. In pain management clinics, where benzodiazepine monitoring is routine, a false negative from a point-of-care test can erode trust between a patient and their provider. In an emergency department, a false positive can send a clinician down the wrong diagnostic path. If you know which type of test was used and the result seems inconsistent with what you are actually taking, the distinction between a rapid cup test and a laboratory immunoassay is worth raising with your provider.

Designer Benzodiazepines and Emerging Challenges

An entirely different wrinkle in benzodiazepine testing has emerged with the spread of designer benzodiazepines, synthetic compounds that are structurally similar to traditional benzodiazepines but not approved for medical use. These substances, which include compounds like flubromazolam, clonazolam, and etizolam, have become increasingly common in illicit drug markets.

Research testing 13 designer benzodiazepines across four commercial immunoassay platforms found that the designer drugs generally showed high cross-reactivity, meaning they triggered positive results on the screening tests.⁹ This creates an unusual situation: the screening test catches something real, but standard confirmatory panels, which are designed to look for prescribed benzodiazepines like diazepam or alprazolam, come up empty. The result looks like a false positive on paper even though the person did consume a benzodiazepine-like substance. One study found that all specimens in such cases showed apparent false-positive screening results because the standard confirmatory LC-MS/MS panel, which targeted 19 prescribed benzodiazepines, detected none of them at measurable levels.¹⁰

For laboratories, this means the definition of “false positive” is shifting. A positive screen that cannot be confirmed by a standard panel might represent a true exposure to a designer compound rather than a cross-reacting medication. For patients and providers, it means that an unexplained positive result cannot always be attributed to a medication side effect. The landscape of what counts as a benzodiazepine in the testing world is expanding faster than the confirmatory panels can keep up with.

What to Do If You Suspect a False Positive

If you receive an unexpected positive benzodiazepine result on a urine drug screen, the most important step is to request confirmatory testing using mass spectrometry. This is your right in most clinical and legal testing contexts, and it is the only way to definitively distinguish a true positive from a cross-reactivity artifact. Before the test, or as soon as possible afterward, provide a complete and honest medication list to the testing provider, including prescription drugs, over-the-counter medications, and supplements. Knowing that you take sertraline, oxaprozin, or efavirenz gives the laboratory a concrete hypothesis to investigate.

Keep in mind that the window for requesting confirmatory testing can be limited. Most testing protocols allow for a sample to be retested from the original specimen within a set timeframe, but if the specimen is discarded, the opportunity is lost. If you are entering a testing situation where the stakes are high, such as a custody evaluation, a probation requirement, or a pre-employment screen, consider bringing documentation of your prescriptions to the appointment. A pharmacy printout or a note from your prescriber can accelerate the resolution process.

In pain management settings, where benzodiazepine testing is used to monitor compliance with treatment agreements, both false positives and false negatives can disrupt care. A false positive may look like unauthorized use of a controlled substance, while a false negative may look like diversion. Either misinterpretation can result in a patient being discharged from a practice. If your test results do not match your actual medication use, ask your provider whether the test was an immunoassay or a confirmatory analysis, and advocate for the more precise method if needed.